Journals / Turkish Journal of Gastroenterology / 2020 / Cilt: 31 - Sayı: 3

Viral hepatitis B and C infections increase the risks of intrahepatic and extrahepatic cholangiocarcinoma: Evidence from a systematic review and meta-analysis

Pages
246–256
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The involvement of AFP, CA19-9, and lymph nodes may play an important role in the diagnosis of CCA

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background/Aims: Previous study has shown a positive relationship between the hepatitis B virus (HBV) or hepatitis C virus (HCV) infection and cholangiocarcinoma (CCA); however, their correlation with different anatomical sites of CCA (i.e.
📊
Key Findings & Data:This study aims to evaluate the association of HBV or HCV infection with CCA, including the intrahepatic cholangiocarcinoma(ICC) and extrahepatic cholangiocarcinoma (ECC), and to determine the roles of α-1 fetoprotein (AFP), CA19-9, and lymph node involvement in CCA with HBV infection.Materials and Methods: Relevant studies published between 2004 and 2016 were systematically searched and retrieved from PubMed,SpringerLink, and Science Direct using key terms such as “cholangiocarcinoma”, “bile duct cancer”, “extrahepatic cholangiocarcinoma”,and “intrahepatic cholangiocarcinoma”.
💡
Conclusion & Impact:The involvement of AFP, CA19-9, and lymph nodes may play an important role in the diagnosis of CCA
🔬Design:Research Article
📍Scope:2004 Verileri
⚙️Variables:Domain Parameters

Özet

Background/Aims: Previous study has shown a positive relationship between the hepatitis B virus (HBV) or hepatitis C virus (HCV) infection and cholangiocarcinoma (CCA); however, their correlation with different anatomical sites of CCA (i.e. ICC and ECC) has not beenrevealed. This study aims to evaluate the association of HBV or HCV infection with CCA, including the intrahepatic cholangiocarcinoma(ICC) and extrahepatic cholangiocarcinoma (ECC), and to determine the roles of α-1 fetoprotein (AFP), CA19-9, and lymph node involvement in CCA with HBV infection.Materials and Methods: Relevant studies published between 2004 and 2016 were systematically searched and retrieved from PubMed,SpringerLink, and Science Direct using key terms such as “cholangiocarcinoma”, “bile duct cancer”, “extrahepatic cholangiocarcinoma”,and “intrahepatic cholangiocarcinoma”. The demographic, clinical, and laboratory data were extracted from the included studies, andthe meta-analysis was performed using RevMan and STATA 11.0 software.Results: A total of 13 studies with CCA matched the inclusion criteria in this meta-analysis, including 7,113 CCA patients and 24,763controls. This meta-analysis showed that the HBV or HCV infections can significantly increase the risk of CCA, including ICC and ECC.In addition, the higher levels of AFP, lower levels of CA19-9, and lymph node involvement were detected in the CCA patients with HBVinfection as compared to those without.Conclusion: The HBV and HCV infections significantly increased the risk of CCA, as well as ICC and ECC. The involvement of AFP, CA19-9, and lymph nodes may play an important role in the diagnosis of CCA

🔖

Cite This Article

TAN, J., ZHOU, W., ZHOU, L., CAO, R., ZHANG, G. (2020). Viral hepatitis B and C infections increase the risks of intrahepatic and extrahepatic cholangiocarcinoma: Evidence from a systematic review and meta-analysis. Turkish Journal of Gastroenterology, Cilt: 31 - Sayı: 3, 246–256. https://ajindex.com/articles/408688

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (3)

  1. World Health Organization. Global hepatitis report. http://www. who.int/hepatitis/publications/global-hepatitis-report2017/en/. Accessed 18 Feb 2018
  2. World Health Organization. Global Health sector strategy on viral hepatitis 2016-2021: Towards ending viral hepatitis. http://apps. who.int/iris/bitstream/10665/246177/1/WHO-HIV-2016.06-eng. pdf?ua=1. Accessed 2 Feb 2018
  3. Cardinale V, Bragazzi MC, Carpino G. Cholangiocarcinoma: increasing burden of classifications. Hepatobiliary Surg Nutr 2013; 2: 272-80. 4. von Hahn T, Ciesek S, Wegener G, et al. Epidemiological trends in incidence and mortality of hepatobiliary cancers in Germany. Scand J Gastroentero 2011; 46: 1092-8. [Crossref] 5. Endo I, Gonen M, Yopp AC, Dalal KM, et al. Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. Ann Surg 2008; 248: 84-96. [Crossref] 6. Bertuccio P, Bosetti C, Levi F, Decarli A, Negri E, La Vecchia C. A comparison of trends in mortality from primary liver cancer and intrahepatic cholangiocarcinoma in Europe. Ann Oncol 2013; 24: 1667-74. [Crossref] 7. Patel T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology 2001; 33: 1353-7. [Crossref] 8. Zhang H, Zhu B, Zhang H, Liang J, Zeng W. HBV Infection Status and the Risk of Cholangiocarcinoma in Asia: A Meta-Analysis. Biomed Res Int 2016; 2016: 3417976. [Crossref] 9. Wang Z, Sheng YY, Dong QZ, Qin LX. Hepatitis B virus and hepatitis C virus play different prognostic roles in intrahepatic cholangiocarcinoma: A meta-analysis. World J Gastroenterol 2016; 22: 3038- 51. [Crossref] 10. Li M, Li J, Li P, et al. Hepatitis B virus infection increases the risk of cholangiocarcinoma: a meta-analysis and systematic review. J Gastroenterol Hepatol 2012; 27: 1561-8. [Crossref] 11. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. JAMA 2000; 283: 2008-12. [Crossref] 12. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010; 25: 603-5. [Crossref] 13. Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 2011; 343: d5928. [Crossref] 14. Ahn CS, Hwang S, Lee YJ, et al. Prognostic impact of hepatitis B virus infection in patients with intrahepa